Cargando…

Use of Glucose-Lowering Agents in Diabetes and CKD

Diabetes is the most common cause of kidney failure worldwide. Patients with diabetes and chronic kidney disease (CKD) are also at markedly higher risk of cardiovascular disease, particularly heart failure (HF), and death. Through the processes of gluconeogenesis and glucose reabsorption, the kidney...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alicic, Radica Z., Neumiller, Joshua J., Galindo, Rodolfo J., Tuttle, Katherine R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727535/ https://www.ncbi.nlm.nih.gov/pubmed/36506243 http://dx.doi.org/10.1016/j.ekir.2022.09.018

Ejemplares similares

Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease
por: Alicic, Radica Z., et al.
Publicado: (2023)

Erratum. Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes 2019;68:248–257
por: Alicic, Radica Z., et al.
Publicado: (2019)

Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium–Glucose Co-transporter-2 Inhibitors
por: Neumiller, Joshua J, et al.
Publicado: (2022)

Glycemic Variability and KIM-1–Induced Inflammation in the Diabetic Kidney
por: Tuttle, Katherine R., et al.
Publicado: (2021)

Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry
por: Tuttle, Katherine R., et al.
Publicado: (2019)

Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD
por: Norris, Keith C., et al.
Publicado: (2019)

Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
por: Nicholas, Susanne B., et al.
Publicado: (2022)

Medication use, renin–angiotensin system inhibitors, and acute care utilization after hospitalization in patients with chronic kidney disease
por: Neumiller, Joshua J, et al.
Publicado: (2020)

Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths
por: Dieter, Brad P., et al.
Publicado: (2015)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
por: Neumiller, Joshua J
Publicado: (2014)

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
por: Infante, Marco, et al.
Publicado: (2022)

Diabetes, bone and glucose-lowering agents: basic biology
por: Lecka-Czernik, Beata
Publicado: (2017)

COVID-19 and Gastrointestinal Tract Symptoms: Recognition, Containment, and Learning From the Past
por: McDermott, Carmen V., et al.
Publicado: (2020)

In Reply — Neutralization of Fecal Aerosol-Laden SARS CoV-2: Public Health Implications
por: McDermott, Carmen V., et al.
Publicado: (2021)

Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016
por: Zhao, Julie Z., et al.
Publicado: (2020)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Diabetes Spectrum: Past, Present, and Future
por: Neumiller, Joshua J.
Publicado: (2018)

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
por: Neumiller, Joshua J.
Publicado: (2014)

Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
por: de Boer, Ian H., et al.
Publicado: (2022)

Continuous glucose monitoring for inpatient diabetes management: an update on current evidence and practice
por: Zelada, Henry, et al.
Publicado: (2023)

The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus
por: Lv, You, et al.
Publicado: (2018)

Management of Hyperglycemia in Diabetic Kidney Disease
por: Neumiller, Joshua J., et al.
Publicado: (2015)

The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus
por: Lexis, Chris PH, et al.
Publicado: (2009)

Optimizing Multidisciplinary Care of Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
por: Kelepouris, Ellie, et al.
Publicado: (2023)

Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review
por: Chan, Siew Pheng, et al.
Publicado: (2023)

Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2018)

From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Neumiller, Joshua J, et al.
Publicado: (2010)

2018 Standards of Care Update: Pharmacologic Approaches to Glycemic Management in People With Type 2 Diabetes
por: Neumiller, Joshua J., et al.
Publicado: (2018)

Uric acid lowering for slowing CKD progression after the CKD-FIX trial: a solved question or still a dilemma?
por: Leoncini, Giovanna, et al.
Publicado: (2022)

Continuous Glucose Monitoring Metrics in the Assessment of Glycemia in Moderate-to-Advanced CKD in Diabetes
por: Ling, James, et al.
Publicado: (2022)

Preventing CKD in Developed Countries
por: Luyckx, Valerie A., et al.
Publicado: (2019)

Lower serum calcium is independently associated with CKD progression
por: Janmaat, Cynthia J., et al.
Publicado: (2018)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

Diabetic Nephropathy and CKD—Analysis of Individual Patient Serum Creatinine Trajectories: A Forgotten Diagnostic Methodology for Diabetic CKD Prognostication and Prediction
por: Onuigbo, Macaulay Amechi Chukwukadibia, et al.
Publicado: (2015)

Effects of glucose-lowering agents on cardiorespiratory fitness
por: Hamasaki, Hidetaka
Publicado: (2018)

Effects of glucose-lowering agents on ischemic stroke
por: Avgerinos, Konstantinos, et al.
Publicado: (2017)

Beyond Blood Glucose and Blood Pressure Control in Type 2 Diabetes: Alternative Management Strategies to Prevent the Development and Progression of CKD
por: Wright, Wendy L., et al.
Publicado: (2023)

Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKD
por: Presswala, Lubaina, et al.
Publicado: (2019)

CKD-MBD after kidney transplantation
por: Wesseling-Perry, Katherine, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_99pah5i7f5nhp9b8tduhmh6si2